THE UNITED STATES PHARMACOPEIAL CONVENTION

Lobbying for THE UNITED STATES PHARMACOPEIAL CONVENTION

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$100,000.00

What this organization spent lobbying with its own staff. Reported using B: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 6

HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
HR 4779
National Security, Department of State, and Related Programs Appropriations Act, 2026
S 2296
National Defense Authorization Act for Fiscal Year 2026
S 1784
MAPS Act
HR 4191
MAPS Act

Lobbying activity 3

Budget/Appropriations

H.R. 5304, S.2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 4779 National Security, Department of State, and Related Programs Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience.

Defense

S. 2296 - National Defense Authorization Act for Fiscal Year 2026: Provisions regarding medicine supply chain.

Health Issues

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.